High Prevalence of Serum Antibodies to Equine Infectious Anemia Virus Reverse Transcriptase

1993 ◽  
Vol 9 (1) ◽  
pp. 7-11 ◽  
Author(s):  
ANTHONY L. DeVICO ◽  
CHARLES J. ISSEL ◽  
STUART F. J. Le GRICE ◽  
SUSAN L. PAYNE ◽  
RONALD C. MONTELARO ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Equine Infectious Anemia Virus ◽  
Serum Antibodies ◽  
High Prevalence ◽  
Equine Infectious Anemia ◽  
Anemia Virus

scholarly journals Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain

2005 ◽  
Vol 86 (1) ◽  
pp. 139-149 ◽  
Author(s):  
Laryssa Howe ◽  
Jodi K. Craigo ◽  
Charles J. Issel ◽  
Ronald C. Montelaro
Keyword(s):  
Immune Suppression ◽  
Neutralizing Antibodies ◽  
Equine Infectious Anemia Virus ◽  
Antibody Responses ◽  
Serum Antibodies ◽  
Virus Envelope ◽  
Specific Serum ◽  
Surface Envelope ◽  
Equine Infectious Anemia ◽  
Anemia Virus

It has been previously reported that transient corticosteroid immune suppression of ponies experimentally infected with a highly neutralization resistant envelope variant of equine infectious anemia virus (EIAV), designated EIAVΔPND, resulted in the appearance of type-specific serum antibodies to the infecting EIAVΔPND virus. The current study was designed to determine if this induction of serum neutralizing antibodies was associated with changes in the specificity of envelope determinants targeted by serum antibodies or caused by changes in the nature of the antibodies targeted to previously defined surface envelope gp90 V3 and V4 neutralization determinants. To address this question, the envelope determinants of neutralization by post-immune suppression serum were mapped. The results demonstrated that the neutralization sensitivity to post-immune suppression serum antibodies mapped specifically to the surface envelope gp90 V3 and V4 domains, individually or in combination. Thus, these data indicate that the development of serum neutralizing antibodies to the resistant EIAVΔPND was due to an enhancement of host antibody responses caused by transient immune suppression and the associated increase in virus replication.

Purification and partial characterization of equine infectious anemia virus reverse transcriptase

Virology ◽  
1991 ◽  
Vol 185 (1) ◽  
pp. 387-394 ◽  
Author(s):  
Anthony Devico ◽  
Ronald C. Montelaro ◽  
Robert C. Gallo ◽  
M.G. Sarngadharan
Keyword(s):  
Reverse Transcriptase ◽  
Equine Infectious Anemia Virus ◽  
Partial Characterization ◽  
Equine Infectious Anemia ◽  
Anemia Virus

scholarly journals Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase.

1991 ◽  
Vol 65 (12) ◽  
pp. 7004-7007 ◽  
Author(s):  
S F Le Grice ◽  
M Panin ◽  
R C Kalayjian ◽  
N J Richter ◽  
G Keith ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Equine Infectious Anemia Virus ◽  
Purification And Characterization ◽  
Equine Infectious Anemia ◽  
Anemia Virus

scholarly journals Serological Method Using Recombinant S2 Protein To Differentiate Equine Infectious Anemia Virus (EIAV)-Infected and EIAV-Vaccinated Horses

2004 ◽  
Vol 11 (6) ◽  
pp. 1120-1129 ◽  
Author(s):  
Sha Jin ◽  
Charles J. Issel ◽  
Ronald C. Montelaro
Keyword(s):  
Vaccine Strain ◽  
Equine Infectious Anemia Virus ◽  
Genetically Engineered ◽  
Commercial Application ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Antibodies ◽  
Serological Method ◽  
Live Virus ◽  
Equine Infectious Anemia ◽  
Anemia Virus

ABSTRACT We recently reported a highly protective attenuated live virus vaccine for equine infectious anemia virus (EIAV) based on a proviral construct (EIAVUKΔS2) with a genetically engineered mutation in the viral S2 gene that eliminates expression of this accessory protein. While the EIAVUKΔS2 vaccine provides protection from detectable infection by experimental challenge with highly virulent virus, the potential for commercial application of this vaccine is complicated by the fact that horses inoculated with the EIAVUKΔS2 vaccine strain become seropositive in various reference diagnostic assays based on detection of antibodies to virion core or envelope proteins. To address this issue, we describe here the development and optimization of a new serologic EIAV diagnostic enzyme-linked immunosorbent assay (ELISA) to detect serum antibodies to the EIAV S2 protein that are produced in infected horses but not in horses inoculated with the EIAVUKΔS2 vaccine virus. The test S2 protein antigen was developed using the S2 gene sequence from the EIAVUK strain of virus and a series of modifications to facilitate production and purification of the diagnostic antigen, designated HS2G. Using this HS2G as antigen, we describe the development of an affinity ELISA that provides a sensitive and specific detection of S2-specific serum antibodies in experimentally and field-infected horses (22 of 24), without detectable reactivity with immune serum from uninfected (12 of 12) or vaccinated (29 of 29) horses. These data indicate that the S2-based diagnostic ELISA has the potential to accurately differentiate horses infected with EIAV from horses inoculated with an attenuated EIAV vaccine strain with a mutant S2 gene.

scholarly journals The catalytic properties of the reverse transcriptase of the lentivirus equine infectious anemia virus

1994 ◽  
Vol 219 (3) ◽  
pp. 977-983 ◽  
Author(s):  
Tami RUBINEK ◽  
Shoshana LOYA ◽  
Miriam SHAHARABANY ◽  
Stephen H. HUGHES ◽  
Patrick K. CLARK ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Equine Infectious Anemia Virus ◽  
Catalytic Properties ◽  
Equine Infectious Anemia ◽  
Anemia Virus
Sign in / Sign up

Export Citation Format

Share Document